Related Experiment Video
Updated: Sep 9, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Upregulation of EMP3 in acute myeloid leukemia: a study based on data mining, RT-qPCR and immunohistochemistry
Angui Liu1, Cong Yu2, Xianwei Peng1
1Department of Hematology, The Second Affiliated Hospital of Guangxi Medical University, No.166, Daxue Road, Nanning, 530000, Guangxi Zhuang Autonomous Region, People's Republic of China.
Background:
Epithelial Membrane Protein 3 (EMP3) has been associated with multiple malignancies, but its expression patterns and clinical significance in acute myeloid leukemia (AML) remain poorly characterized.
Methods:
Public datasets were integrated to assess EMP3 mRNA expression levels in AML patients versus healthy donors, with validation performed using reverse transcription quantitative PCR (RT-qPCR). Protein expression was accessed through immunohistochemistry. Prognosis relevance was evaluated via survival analysis. Molecular mechanisms were investigated using weighted gene co-expression network analysis (WGCNA), single-cell RNA sequencing, immune infiltration assessment, and pathway enrichment analysis.
Results:
Elevated EMP3 expression was detected in AML samples relative to healthy donors, showing a standardized mean difference (SMD) of 0.84 (95% CI: 0.63, 1.05). This upregulation was validated by RT-qPCR and immunohistochemical analyses, yielding a consistent SMD of 0.94 (95% CI: 0.57, 1.32) when RT-qPCR data were included. Prognostic assessment indicated a significant association between EMP3 levels and AML clinical outcomes. Among 829 genes co-expressed with EMP3, enrichment was observed in acute myeloid leukemia-related pathways, with BCL2A1 and ITGAM identified as hub co-expressed genes.
Conclusion:
These findings suggest that EMP3 overexpression occurs in AML and potentially influences disease prognosis.
Insights
Epithelial Membrane Protein 3 (EMP3) is overexpressed in acute myeloid leukemia (AML), and its levels are linked to patient prognosis. Further research is needed to understand its role in AML development.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Epithelial Membrane Protein 3 (EMP3) is implicated in various cancers.
- Its role in acute myeloid leukemia (AML) is not well understood.
Purpose of the Study:
- To investigate EMP3 expression patterns in AML.
- To determine the clinical significance and prognostic value of EMP3 in AML.
- To explore the molecular mechanisms underlying EMP3's function in AML.
Main Methods:
- Analysis of public datasets for EMP3 mRNA expression in AML patients and healthy donors.
- Validation of EMP3 expression using reverse transcription quantitative PCR (RT-qPCR) and immunohistochemistry.
- Prognostic evaluation through survival analysis.
- Investigation of molecular mechanisms via weighted gene co-expression network analysis (WGCNA), single-cell RNA sequencing, and pathway enrichment analysis.
Main Results:
- EMP3 mRNA and protein expression were significantly elevated in AML samples compared to healthy controls.
- Higher EMP3 levels were associated with poorer clinical outcomes in AML patients.
- Pathway enrichment analysis identified AML-related pathways and key co-expressed genes (BCL2A1, ITGAM) linked to EMP3.
Conclusions:
- EMP3 is overexpressed in acute myeloid leukemia.
- EMP3 expression levels may serve as a prognostic biomarker in AML.
- EMP3 potentially plays a role in AML pathogenesis and progression.
More Related Videos
13:34Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip
Published on: September 29, 2012
12:44Identification of Key Factors Regulating Self-renewal and Differentiation in EML Hematopoietic Precursor Cells by RNA-sequencing Analysis
Published on: November 11, 2014